Key result
POLARx cryoballoon shows similar acute pulmonary vein isolation rates to AFA-Pro despite longer initial procedures.
Why the study?
A novel cryoballoon system maintaining constant balloon pressure recently became available for atrial fibrillation, prompting a comparison of its procedural efficacy and biophysical characteristics against an established system.
Does the POLARx cryoballoon system provide comparable acute pulmonary vein isolation efficacy to the AFA-Pro system in patients with atrial fibrillation?
Comparison
POLARx (n = 57) vs AFA-Pro (n = 53)
Design
Multicenter prospective cohort study
Authors
Loading...
Similar acute PVI rates in this cohort should not change practice; leaves open whether cooling differences affect durability.
Cohort (n=110)
Yes
Does the POLARx cryoballoon system provide comparable acute pulmonary vein isolation efficacy to the AFA-Pro system in patients with atrial fibrillation?
Absolute Event Rate: 99.5% vs 100%
p-value: p=1.00
The novel POLARx cryoballoon system demonstrates comparable acute procedural efficacy and safety to the established AFA-Pro system for pulmonary vein isolation, despite slightly different biophysical cooling profiles.
Yap et al. (2021) conducted a cohort in Atrial fibrillation (n=110). POLARx cryoballoon vs. Arctic Front Advance Pro (AFA-Pro) cryoballoon was evaluated on Acute pulmonary vein isolation (p=1.00). The POLARx cryoballoon achieved similar acute pulmonary vein isolation rates compared to the AFA-Pro system (99.5% vs. 100%, p=1.00), with faster cooling rates but initially longer procedure times.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: